TFA Therapeutics (RAJAF) Liabilities and Shareholders Equity (2020 - 2025)

TFA Therapeutics has reported Liabilities and Shareholders Equity for 6 years, with the latest figure at $4.7 million in Q4 2025.

• On a quarterly basis, Liabilities and Shareholders Equity rose 0.73% year-over-year to $4.7 million in Q4 2025; TTM through Dec 2025 was $14.4 million, a 21.49% increase from a year earlier, with the FY2025 full-year figure at $4.7 million, up 0.73% from the prior year.
• Liabilities and Shareholders Equity was $4.7 million for Q4 2025 at TFA Therapeutics, up from $4.6 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $4.7 million in Q4 2025, with the low at $1.8 million in Q3 2023.
• Average Liabilities and Shareholders Equity over 5 years is $3.3 million, with a median of $3.3 million recorded in 2021.
• The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity plunged 35.49% in 2022, then jumped 59.24% in 2023.
• Over 5 years, Liabilities and Shareholders Equity stood at $3.3 million in 2021, then plunged by 35.49% to $2.1 million in 2022, then soared by 59.24% to $3.4 million in 2023, then jumped by 37.95% to $4.6 million in 2024, then grew by 0.73% to $4.7 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $4.7 million (Q4 2025), $4.6 million (Q4 2024), and $3.4 million (Q4 2023), per Business Quant data.